drugset / Trial / NCT05866861
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
RandomizedSequentialQuadruple-blindTreatment
Summary
The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).
Timeline
- Start
- 2023-04-24
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CUG252 | Unknown | — | Subcutaneous |